公开(公告)号：US20090192166A1

公开(公告)日：2009-07-30

申请号：US12397806

申请日：2009-03-04

申请人： Ranga R. Krishnan ,  Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinova ,  Tatiana D. Sotnikova

发明人： Ranga R. Krishnan ,  Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinova ,  Tatiana D. Sotnikova

IPC分类号： A61K31/405 ,  A61K31/519 ,  A61K31/4525 ,  A61K31/343 ,  A61K31/195 ,  A61K31/15 ,  A61K31/136 ,  A61K31/138

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/14 ,  A61K31/343 ,  A61K31/405 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

摘要： A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.

摘要翻译： 用于治疗受试者血清素能神经递质调节障碍的方法包括以有效治疗该病症的量施用受试者血清素增强剂（例如5-羟色胺再摄取抑制剂）; 并且以有效增强5-羟色胺增强剂（例如5-羟色胺再摄取抑制剂）的活性的量同时施用受试者5-羟色氨酸。 在优选的实施方案中，该疾病是抑郁，焦虑或药物滥用。

公开(公告)号：US07517908B2

公开(公告)日：2009-04-14

申请号：US11133867

申请日：2005-05-20

申请人： Ranga R. Krishnan ,  Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinova ,  Tatiana D. Sotnikova

发明人： Ranga R. Krishnan ,  Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinova ,  Tatiana D. Sotnikova

IPC分类号： A01N43/08 ,  A61K31/34 ,  G01N33/566 ,  G01N33/567 ,  C12Q1/00 ,  C12Q1/68

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/14 ,  A61K31/343 ,  A61K31/405 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

摘要： A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.

摘要翻译： 用于治疗受试者血清素能神经递质调节障碍的方法包括以有效治疗该病症的量施用受试者血清素增强剂（例如5-羟色胺再摄取抑制剂）; 并且同时以有效增强5-羟色胺核酸激酶（例如5-羟色胺再摄取抑制剂）的活性的量施用受试者5-羟色氨酸。 在优选的实施方案中，该疾病是抑郁，焦虑或药物滥用。

公开(公告)号：US07585627B2

公开(公告)日：2009-09-08

申请号：US11133949

申请日：2005-05-20

申请人： Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinov ,  Tatiana D. Sotnikova ,  Ranga R. Krishnan ,  David A. Schwartz ,  Lauranell Burch ,  Redford B. Williams

发明人： Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinov ,  Tatiana D. Sotnikova ,  Ranga R. Krishnan ,  David A. Schwartz ,  Lauranell Burch ,  Redford B. Williams

IPC分类号： C12Q1/68 ,  G01N33/567 ,  C12P19/34

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/14 ,  A61K31/343 ,  A61K31/405 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

摘要： A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.

摘要翻译： 筛选受试者血清素能神经递质调节障碍的方法包括检测受试者中Tph2突变的存在或不存在; 然后确定由于存在或不存在Tph2突变，受试者处于血清素能神经传递失调障碍的风险增加。

公开(公告)号：US20100256116A1

公开(公告)日：2010-10-07

申请号：US12510590

申请日：2009-07-28

申请人： Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinov ,  Tatiana D. Sotnikova ,  Ranga R. Krishnan ,  David A. Schwartz ,  Redford B. Williams ,  Lauranell Burch

发明人： Marc G. Caron ,  Xiaodong Zhang ,  Martin Beaulieu ,  Raul R. Gainetdinov ,  Tatiana D. Sotnikova ,  Ranga R. Krishnan ,  David A. Schwartz ,  Redford B. Williams ,  Lauranell Burch

IPC分类号： A61K31/55 ,  C12Q1/68 ,  A61K31/131 ,  A61K31/135 ,  A61K31/343 ,  A61K31/4525 ,  A61P25/24

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/14 ,  A61K31/343 ,  A61K31/405 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

摘要： A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.

摘要翻译： 筛选受试者血清素能神经递质调节障碍的方法包括检测受试者中Tph2突变的存在或不存在; 然后确定由于存在或不存在Tph2突变，受试者处于血清素能神经传递失调障碍的风险增加。

公开(公告)号：US20220187315A1

公开(公告)日：2022-06-16

申请号：US17438156

申请日：2020-03-06

申请人： Rima F. KADDURAH-DAOUK ,  John A. RUSH ,  Siamk Mahmoudian DEHKORDI ,  Sudeepa BHATTCHARYYA ,  Ranga R. KRISHNAN ,  Mark A. FRYE ,  Ahmed T. AHMED ,  Richard M. WEINSHILBOUM ,  Boadie W. DUNLOP ,  Wei JIA ,  Duke University ,  UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES ,  RUSH MEDICAL COLLEGE ,  MAYO CLINIC ,  EMORY UNIVERSITY SCHOOL OF MEDICINE ,  UNIVERSITY OF HAWAII CANCER CENTER

发明人： Rima F. Kaddurah-Daouk ,  Augustus John Rush, Jr. ,  Siamak Mahmoudian Dehkordi ,  Sudeepa Bhattcharyya ,  Ranga R. Krishnan ,  Mark A. Frye ,  Ahmed T. Ahmed ,  Richard M. Weinshilboum ,  Boadie W. Dunlop ,  Wei Jia

IPC分类号： G01N33/68 ,  G01N33/92 ,  G01N33/94 ,  A61P25/24

摘要： Described herein are methods and composition for diagnosing and evaluating the treatment of depression using one or more biomarker metabolites for the diagnosis and monitoring treatment efficacy. In one aspect, the biomarker metabolites can be used to screen subjects for the likelihood of developing depression, the diagnosis thereof, monitoring the efficacy of treatment, and evaluating a subject's propensity for responding to treatment.